Abstract:Protein kinases play pivotal roles in various biological functions, influencing cell differentiation, promoting survival, and regulating the cell cycle. The disruption of protein kinase activity is intricately linked to pathways in tumor development. This manuscript explores the transformative impact of protein kinase inhibitors on cancer therapy, particularly their efficacy in cases driven by targeted mutations. Focusing on key tyrosine kinase inhibitors (TKIs) like Bcr-Abl, Epidermal Growth Factor Receptor (EGFR), and Vascular Endothelial Growth Factor Receptor (VEGFR), it targets critical kinase families in cancer progression. Clinical trial details of these TKIs offer insights into their therapeutic potentials. Learning from FDA-approved kinase inhibitors, the review dissects trends in kinase drug development since imatinib's paradigm-shifting approval in 2001. TKIs have evolved into pivotal drugs, extending beyond oncology. Ongoing clinical trials explore novel kinase targets, revealing the vast potential within the human kinome. The manuscript provides a detailed analysis of advancements until 2022, discussing the roles of specific oncogenic protein kinases in cancer development and carcinogenesis. Our exploration on PubMed for relevant and significant TKIs undergoing pre-FDA approval phase III clinical trials enriches the discussion with valuable findings. While kinase inhibitors exhibit lower toxicity than traditional chemotherapy in cancer treatment, challenges like resistance and side effects emphasize the necessity of understanding resistance mechanisms, prompting the development of novel inhibitors like osimertinib targeting specific mutant proteins. The review advocates thorough research on effective combination therapies, highlighting the future development of more selective RTKIs to optimize patient-specific cancer treatment and reduce adverse events.

Kinase inhibitors: the road ahead

Kinase-targeted cancer therapies: progress, challenges and future directions

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors

Trends in kinase drug discovery: targets, indications and inhibitor design

Kinase Inhibitors FDA-Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities

The Prospect of Substrate-Based Kinase Inhibitors to Improve Target Selectivity and Overcome Drug Resistance.

Targeting cancer with small molecule kinase inhibitors

Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors

Kinase drug discovery 20 years after imatinib: progress and future directions

FDA-approved small molecule kinase inhibitors for cancer treatment (2001-2015): Medical indication, structural optimization, and binding mode Part I

Tyrosine kinase inhibitors in cancer treatment (Part II)

Kinase inhibitors: 20 years of success and many new challenges and recent trends in their patents

Irreversible Kinase Inhibitors Targeting Cysteine Residues and their Applications in Cancer Therapy

Fyn, Blk, and Lyn kinase inhibitors: A mini-review on medicinal attributes, research progress, and future insights

A comprehensive review of protein kinase inhibitors for cancer therapy

Tyrosine kinase inhibitors: a clinical perspective

Tyrosine kinase inhibitors in cancers: Treatment optimization - Part I

Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

CADD Methods for Developing Novel Compounds Synthesized to Inhibit Tyrosine Kinase Receptors